专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022192202A1 BELVARAFENIB FOR USE IN TREATMENT OF BRAIN CANCERS 审中-公开
公开(公告)号：WO2022192202A1
公开(公告)日：2022-09-15
申请号：PCT/US2022/019273
申请日：2022-03-08
申请人： GENENTECH, INC. , F. HOFFMANN-LA ROCHE AG , HOFFMANN-LA ROCHE INC. , HANMI PHARM. CO., LTD.
发明人： ADAMKEWICZ, Joanne , DOLTON, Michael John , MALEK, Shiva , THOMAS, Piia , ENG-WONG, Jennifer , YAN, Yibing , KIM, Young Hoon , AHN, Young Gil , KIM, Yu Yon
IPC分类号： A61K31/4523 , A61K31/519 , A61P35/04
摘要： Provided are methods for the use of belvarafenib to treat brain cancer including metastatic brain cancer carrying a BRAF mutation, a NRAS mutation, a KRAS mutation, or a combination thereof.

2. 发明申请

WO2020022600A1 PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME 审中-公开
公开(公告)号：WO2020022600A1
公开(公告)日：2020-01-30
申请号：PCT/KR2019/001737
申请日：2019-02-13
申请人： HANMI PHARM. CO., LTD.
发明人： BAE, In Hwan , KIM, Ji Sook , CHOI, Jae Yul , KANG, Seok Jong , AHN, Young Gil , SUH, Kwee Hyun
IPC分类号： C07D403/14 , A61K31/506 , A61K31/496 , A61P35/00 , A61P35/02
摘要： Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.

3. 发明申请

WO2018084627A3 PHARMACEUTICAL COMPLEX FORMULATION COMPRISING AMLODIPINE, LOSARTAN AND CHLORTHALIDONE 审中-公开
公开(公告)号：WO2018084627A3
公开(公告)日：2018-05-11
申请号：PCT/KR2017/012396
申请日：2017-11-03
申请人： HANMI PHARM. CO., LTD.
发明人： CHO, Hyuk Jun , LIM, Sol Ee , IM, Ho Taek , KIM, Yong Il , PARK, Jae Hyun , WOO, Jong Soo
IPC分类号： A61K9/20 , A61K31/4422 , A61K31/4178 , A61K31/404
摘要： The present invention relates to a pharmaceutical complex formulation including amlodipine, losartan, and chlorthalidone as active ingredients. The pharmaceutical complex formulation of the present invention including amlodipine, losartan and chlorthalidone as the active ingredients exhibits excellent dissolution characteristics of the active ingredients, and has high content uniformity and heat stability. Therefore, the complex formulation of the present invention can be used as a prophylactic or therapeutic agent for cardiovascular diseases, which has excellent quality and heat stability.

4. 发明申请

WO2017131298A1 COMBINATION OF CROSS-LINKED HYALURONIC ACIDS AND METHOD OF PREPARING THE SAME 审中-公开
标题翻译：交联的透明质酸的组合及其制备方法
公开(公告)号：WO2017131298A1
公开(公告)日：2017-08-03
申请号：PCT/KR2016/005819
申请日：2016-06-01
申请人： HANMI PHARM. CO., LTD.
发明人： CHOI, Sung Chul , KIM, Hyun Il , YANG, Ki Young , PARK, Hyo Seung , LEE, Back Ho
IPC分类号： C08B37/08 , A61K47/36 , A61K9/00 , A61K31/728
CPC分类号： A61K47/36 , A61K31/728 , C08B37/0072
摘要： Provided are a method of preparing a cross-linked hyaluronic acid having an elasticity of about 50 to about 200 Pa and a viscosity of about 20 to about 100 Pa, the method including cross-linking hyaluronic acid with an epoxy-based cross-linking agent having at least two epoxy functional groups in an ethanol-containing aqueous alkaline; a method of preparing a cross-linked hyaluronic acid having an elasticity of about 400 to about 800 Pa and a viscosity of about 40 to about 100 Pa, the method including cross-linking the cross-linked hyaluronic acid having an elasticity of about 50 to about 200 Pa and a viscosity of about 20 to about 100 Pa with an epoxy-based cross-linking agent having at least two epoxy functional groups in an aqueous alkaline solution; and a combination of cross-linked hyaluronic acids including the cross-linked hyaluronic acid having an elasticity of about 50 to about 200 Pa and a viscosity of about 20 to about 100 Pa and the cross-linked hyaluronic acid having an elasticity of about 400 to about 800 Pa and a viscosity of about 40 to about 100 Pa.
摘要翻译：提供了一种制备具有约50至约200Pa的弹性和约20至约100Pa的粘度的交联透明质酸的方法，所述方法包括将透明质酸与在含乙醇的碱性水溶液中具有至少两个环氧官能团的基于环氧的交联剂; 制备具有约400至约800Pa的弹性和约40至约100Pa的粘度的交联透明质酸的方法，所述方法包括交联弹性为约50至约100的交联透明质酸约200Pa的粘度和约20至约100Pa的粘度，其中在碱性水溶液中具有至少两个环氧官能团的环氧基交联剂; 以及交联透明质酸的组合，所述交联透明质酸包括具有约50至约200Pa的弹性和约20至约100Pa的粘度的交联透明质酸和具有约400至约100Pa的弹性的交联透明质酸约800Pa和约40至约100Pa的粘度

5. 发明申请

WO2017003191A1 GLUCAGON DERIVATIVE AND A COMPOSITION COMPRISING A LONG ACTING CONJUGATE OF THE SAME 审中-公开
标题翻译： GLUCAGON衍生物和包含其长期活性成分的组合物
公开(公告)号：WO2017003191A1
公开(公告)日：2017-01-05
申请号：PCT/KR2016/006984
申请日：2016-06-29
申请人： HANMI PHARM. CO., LTD.
发明人： LEE, Jong Suk , LEE, Jong Min , PARK, Young Jin , LIM, Chang Ki , JUNG, Sung Youb , KWON, Se Chang
IPC分类号： A61K38/26 , A61K38/28
CPC分类号： C07K14/605 , A61K38/2264 , A61K38/2278 , A61K38/26 , A61K38/28 , A61K47/60 , A61K47/68 , A61K47/6811 , A61P3/00 , A61P3/04 , A61P3/08 , A61K2300/00
摘要： The present invention relates to a glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof.
摘要翻译：本发明涉及胰高血糖素衍生物，胰高血糖素衍生物的长效缀合物及其用途。

6. 发明申请

WO2016108617A1 GLUCAGON DERIVATIVES 审中-公开
标题翻译： GLUCAGON衍生物
公开(公告)号：WO2016108617A1
公开(公告)日：2016-07-07
申请号：PCT/KR2015/014481
申请日：2015-12-30
申请人： HANMI PHARM. CO., LTD.
发明人： JUNG, Sung Youb , PARK, Young Jin , LEE, Jong Suk , CHOI, Jae Hyuk , LIM, Chang Ki , KWON, Se Chang
IPC分类号： C07K14/605 , A61K38/26 , A61P3/04
CPC分类号： C07K14/605 , A61K38/00 , A61K38/26 , A61K45/06
摘要： The present invention relates to a novel peptide of a glucagon derivative and a composition for preventing or treating obesity comprising the peptide as an active ingredient. The glucagon derivative according to the present invention shows a more excellent activating effect with regard to both glucagon-like peptide-1 receptors and glucagon receptors compared to native glucagon, and thus can be widely used as an effective agent for treating obesity.
摘要翻译：本发明涉及一种胰高血糖素衍生物的新型肽和用于预防或治疗包含该肽作为活性成分的肥胖症的组合物。根据本发明的胰高血糖素衍生物与天然胰高血糖素相比，对胰高血糖素样肽-1受体和胰高血糖素受体两者显示出更优异的活化作用，因此可广泛用作治疗肥胖症的有效药剂。

7. 发明申请

WO2016052897A1 DRY POWDER FOR INHALATION FORMULATION HAVING IMPROVED STABILITY OF COMBINED ACTIVE INGREDIENTS 审中-公开
标题翻译：用于吸入配方的干粉配合组合活性成分的改进稳定性
公开(公告)号：WO2016052897A1
公开(公告)日：2016-04-07
申请号：PCT/KR2015/009918
申请日：2015-09-22
申请人： HANMI PHARM. CO., LTD.
发明人： CHO, Hyuk Jun , YOON, Young Min , KIM, Kyeong Soo , PARK, Jae Hyun , WOO, Jong Soo
IPC分类号： A61K9/14 , A61K9/16 , A61K31/56 , A61K31/166
CPC分类号： A61K31/56 , A61K9/0075 , A61K9/145 , A61K31/137 , A61K31/439 , A61K47/26 , A61K2300/00
摘要： A dry powder for an inhalation formulation and an inhalation formulation including the dry powder. The dry powder includes: at least two combined active ingredients selected from the group consisting of salmeterol or a pharmaceutically acceptable salt thereof, tiotropium or a pharmaceutically acceptable salt thereof, and fluticasone or a pharmaceutically acceptable salt thereof; and a diluent, wherein the diluent includes about 0.1wt% to about 50wt% of micronized powder having an average particle diameter (X 50 ) of about 30 ㎛ or less based on a total weight of the diluent so that the stability of at least one of the active ingredients is higher than that of a dry powder having a micronized powder content exceeding 50wt%.
摘要翻译：用于吸入制剂的干粉和包含干粉的吸入制剂。所述干粉末包括：至少两种选自沙美特罗或其药学上可接受的盐，噻托溴铵或其药学上可接受的盐和氟替卡松或其药学上可接受的盐的组合活性成分; 和稀释剂，其中所述稀释剂包含基于所述稀释剂的总重量的约0.1重量％至约50重量％的平均粒径（X 50）为约30㎛或更小的微粉化粉末，使得至少一种活性成分高于微粉末含量超过50重量％的干粉的活性成分。

8. 发明申请

WO2016052866A1 SOLID PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE AND LOSARTAN 审中-公开
标题翻译：包含AMLODIPINE和LOSARTAN的固体药物组合物
公开(公告)号：WO2016052866A1
公开(公告)日：2016-04-07
申请号：PCT/KR2015/009203
申请日：2015-09-01
申请人： HANMI PHARM. CO., LTD.
发明人： ROH, Leedong , IM, Ho Taek , YOON, Young Su , KIM, Yong Il , PARK, Jae Hyun , WOO, Jong Soo
IPC分类号： A61K31/4178 , A61K31/44 , A61K31/417 , A61K9/14
CPC分类号： A61K31/417 , A61K9/2027 , A61K9/2059 , A61K9/2077 , A61K31/4178 , A61K31/44 , A61K31/4422 , A61K2300/00
摘要： The present invention provides a pharmaceutical composition for the prevention or treatment of cardiovascular disorders containing losartan or a pharmaceutically acceptable salt thereof; amlodipine or a pharmaceutically acceptable salt thereof; a disintegrant; and a coating agent. The composition of the present invention, which has the best combination and optimum ratio of a disintegrant to a coating agent, shows sufficient strength and high dissolution rates under various pH environments, and thus, it is useful for the preparation of an excellent solid formulation exhibiting improved drug delivery efficiency and storage stability. Representative Drawing: Fig. 1
摘要翻译：本发明提供了用于预防或治疗含有氯沙坦或其药学上可接受的盐的心血管疾病的药物组合物; 氨氯地平或其药学上可接受的盐; 崩解剂和涂层剂。具有崩解剂与包衣剂的最佳组合和最佳比例的本发明的组合物在各种pH环境下显示出足够的强度和高溶解速率，因此可用于制备优异的固体制剂展示提高药物输送效率和储存稳定性。代表图： 1

9. 发明申请

WO2016043533A1 USE OF A LONG ACTING GLP-1/GLUCAGON RECEPTOR DUAL AGONIST FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE 审中-公开
标题翻译：使用长效GLP-1 / GLUCAGON受体双因素治疗非酒精性脂肪肝疾病
公开(公告)号：WO2016043533A1
公开(公告)日：2016-03-24
申请号：PCT/KR2015/009753
申请日：2015-09-16
申请人： HANMI PHARM. CO., LTD.
发明人： HWANG, Sang Youn , KIM, Jin Young , KIM, Seung Su , CHOI, In Young , JUNG, Sung Youb , KWON, Se Chang
IPC分类号： A61K38/26 , A61K47/48 , A61P1/16
CPC分类号： C07K16/00 , A61K38/26 , A61K47/48215 , A61K47/48415 , A61K47/60 , A61K47/6811 , A61K49/0008 , C07K2317/41 , C07K2317/53
摘要： The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting GLP-1/glucagon receptor dual agonist, and a method for preventing or treatment of non-alcoholic fatty liver disease including administering the composition. The composition of the present invention either has no side effect of weight gain or reduces the side effect of weight gain, which is a side-effect of conventional therapeutic agents for non-alcoholic fatty liver disease, and reduces the amount of administrations of a long-acting GLP-1/glucagon receptor dual agonist, thus greatly improving patient's convenience. In addition, the long-acting GLP-1/glucagon receptor dual agonist of the present invention improves in vivo sustainability and stability.
摘要翻译：本发明涉及用于预防或治疗非酒精性脂肪肝疾病的药物组合物，其包括长效GLP-1 /胰高血糖素受体双重激动剂，以及用于预防或治疗非酒精性脂肪肝疾病的方法，包括给予组成。本发明的组合物不具有体重增加的副作用或减轻体重增加的副作用，这是常规治疗剂对非酒精性脂肪肝疾病的副作用，并且减少长时间的给药量 GLP-1 /胰高血糖素受体双重激动剂，从而大大提高了患者的便利性。此外，本发明的长效GLP-1 /胰高血糖素受体双重激动剂改善了体内可持续性和稳定性。

10. 发明申请

WO2014209087A1 PHARMACEUTICAL CAPSULE COMPOSITE FORMULATION COMPRISING TADALAFIL AND TAMSULOSIN 审中-公开
标题翻译：包含TADALAFIL和TAMSULOSIN的药用胶囊复合制剂
公开(公告)号：WO2014209087A1
公开(公告)日：2014-12-31
申请号：PCT/KR2014/005813
申请日：2014-06-30
申请人： HANMI PHARM. CO., LTD.
发明人： PARK, Caleb Hyungmin , KWON, Yoeng Jin , KIM, Yong Il , PARK, Jae Hyun , WOO, Jong Soo , LEE, Seung Yeop , YOON, Young-su
IPC分类号： A61K9/48 , A61K31/4985 , A61K31/18 , A61P13/08
CPC分类号： A61K31/4985 , A61K9/2054 , A61K9/209 , A61K9/4808 , A61K9/5026 , A61K9/5073 , A61K9/5084 , A61K31/18 , A61K2300/00
摘要： Disclosed are a capsule composite formulation for preventing or treating erectile dysfunction and benign prostatic hyperplasia comprising tadalafil and tamsulosin, and a method of preparing the same. The capsule composite formulation of the present invention enables the complete separation of the two pharmaceutically active ingredients and minimizes reactivity between the active ingredients, and thus provides excellent product stability over time, thereby maximizing the therapeutic effects thereof.
摘要翻译：公开了一种用于预防或治疗勃起功能障碍和包括他达拉芬和坦索罗辛的良性前列腺增生的胶囊复合制剂及其制备方法。本发明的胶囊复合制剂能够完全分离两种药物活性成分并使活性成分之间的反应性最小化，从而随时间提供优异的产品稳定性，从而使其治疗效果最大化。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式